Company secures four oral presentations, including three that will
highlight new data demonstrating activity of rezafungin against Candida
auris and azole-resistant Aspergillus
SAN DIEGO –
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company
developing novel anti-infectives including immunotherapies, today
announced that data from preclinical studies of its lead antifungal
rezafungin will be presented at the 28th European Congress of Clinical
Microbiology and Infectious Diseases (ECCMID) to be held in Madrid,
Spain, April 21-24, 2018.
“At this year’s ECCMID meeting Cidara and our collaborators will present
a significant amount of new data highlighting the full utility of
rezafungin in areas of highest unmet need,” said Jeffrey Stein, Ph.D.,
president and chief executive officer of Cidara. “Rezafungin’s potent
efficacy against Candida auris and azole-resistant Aspergillus,
as well as its substantial penetration into the respiratory tract,
strengthens the growing body of evidence differentiating it in the
treatment and prophylaxis of deadly invasive fungal infections.”
ECCMID convenes leading experts from around the world to present and
discuss the latest research findings in infectious diseases, infection
control and clinical microbiology. A total of five presentations at the
2018 ECCMID Congress, comprising four oral presentations and one poster,
will report data evaluating Cidara’s lead antifungal rezafungin, the
only once-weekly product candidate in development for the treatment and
prevention of life-threatening invasive fungal infections.
Details of the five ECCMID presentations are as follows:
Oral Presentations
Title: Multicentre determination of CD101 (rezafungin)
susceptibility of Candida species by the EUCAST method
Author:
Arendrup, et. al.
Date and time: Tuesday, April 24,
9:22-9:32 a.m. CET
Location: Hall K, IFEMA – Feria de Madrid
Presentation
number: #O0938
Oral Session: News on Antifungal Therapy
Title: Rezafungin (CD101) demonstrates potent in vitro activity
against Aspergillus, including azole-resistant A. fumigatus
isolates and cryptic species
Author: Wiederhold, et. al.
Date
and time: Tuesday, April 24, 9:34-9:44 a.m. CET
Location:
Hall K, IFEMA – Feria de Madrid
Presentation number: #O0939
Oral
Session: News on Antifungal Therapy
Title: EUCAST susceptibility testing of rezafungin (CD101):
activity against Candida auris
Author: Arendrup, et.
al.
Date and time: Tuesday, April 24, 10:10-10:20 a.m. CET
Location:
Hall K, IFEMA – Feria de Madrid
Poster number: #O0942
Oral
Session: News on Antifungal Therapy
Title: Pharmacodynamic (PD) evaluation of rezafungin against Candida
auris in the persistently neutropenic murine model of disseminated
candidiasis
Author: Lepak (Andes), et. al.
Date and
time: Tuesday, April 24, 10:34-10:44 a.m. CET
Location: Hall
K, IFEMA – Feria de Madrid
Poster number: #O0944
Oral
Session: News on Antifungal Therapy
Poster Presentation
Title: High and sustained lung epithelial lining fluid
(ELF)-to-plasma exposure ratio from a single dose of rezafungin (CD101):
efficacy comparison to posaconazole and micafungin in a mouse pulmonary
aspergillosis infection model
Author: Ong, et. al.
Date
and time: Saturday, April 21, 3:30-4:30 p.m. CET
Location: Paper
Poster Arena, IFEMA – Feria de Madrid
Poster number: #P0173
Poster
Session: Aspergillus in the Laboratory
Copies of these presentations will be available on the Cidara website
following the meeting: www.cidara.com
About Invasive Fungal Infections
Invasive fungal infections (IFIs) represent a serious threat to millions
of patients worldwide, resulting in more than 1.5 million deaths
annually and mortality rates ranging from 15 to 65 percent. These
infections are especially relevant for patients whose immune systems
have been compromised, such as patients undergoing bone marrow
transplantation (BMT) or chemotherapy. Of the most significant IFIs,
approximately 90 percent of related deaths are primarily caused by Candida,
Aspergillus, and Pneumocystis. Candida auris (also
called C. auris) has become a growing public health concern and
can cause bloodstream infections and even death, particularly in
hospital and nursing home patients with serious medical problems.
According to the Centers for Disease Control and Prevention, more than
one in three patients with invasive C. auris infection die.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on developing
new anti-infectives that have the potential to transform the standard of
care and save or improve patients’ lives. The company is currently
advancing its novel echinocandin antifungal, rezafungin acetate,
formerly known as CD101 IV, through clinical trials. Rezafungin has
improved pharmacokinetics compared to existing echinocandins and the
potential for expanded utility across patient settings. It is the only
once-weekly product candidate in development for the treatment and
prevention of life-threatening invasive fungal infections. The company’s
Phase 2 STRIVE clinical trial of rezafungin met its primary safety and
efficacy objectives, and Cidara plans to initiate Phase 3 pivotal trials
in the treatment of candidemia and invasive candidiasis and the
prophylaxis of invasive fungal infections in 2018. Cidara also is
leveraging its novel Cloudbreak™ platform to develop antibody-drug
conjugates for the treatment of multi-drug resistant Gram-negative
bacterial infections. Cloudbreak is the first immunotherapy discovery
platform designed specifically to create compounds that directly kill
pathogens and also direct a patient’s immune cells to attack and
eliminate bacterial, fungal or viral pathogens. Cidara is headquartered
in San Diego, California. For more information, please visit www.cidara.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are
not historical facts are “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, the potential for rezafungin to successfully treat or prevent
invasive fungal infections and represent an improvement over current
approaches, and Cidara’s ability to successfully develop rezafungin.
Risks that contribute to the uncertain nature of the forward-looking
statements include: the success and timing of Cidara’s preclinical
studies and clinical trials; regulatory developments in the United
States and foreign countries; changes in Cidara’s plans to develop and
commercialize its product candidates; Cidara’s ability to obtain
additional financing; Cidara’s ability to obtain and maintain
intellectual property protection for its product candidates; and the
loss of key scientific or management personnel. These and other risks
and uncertainties are described more fully in Cidara’s Form 10-Q most
recently filed with the United States Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made. Cidara
undertakes no obligation to update such statements to reflect events
that occur or circumstances that exist after the date on which they were
made.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180404005145/en/
Cidara Therapeutics, Inc.
INVESTOR CONTACT:
Westwicke
Partners, LLC
Robert H. Uhl, 858-356-5932
Managing Director
robert.uhl@westwicke.com
or
MEDIA
CONTACT:
Sam Brown Inc.
Christy Curran, 615-414-8668
ChristyCurran@sambrown.com
